Get to know our clinical trials
Clinical trial to evaluate the bioequivalence of Onivyde (irinotecan liposomal injection) manufactured at two different centers and administered in combination with antineoplastics in adult participants with metastatic pancreatic adenocarcinoma.
THE PURPOSE OF THIS CLINICAL TRIAL IS TO COMPARE HOW THE SAME STUDY DRUG, ONIVYDE, IS PROCESSED BY THE BODY WHEN MANUFACTURED AT TWO DIFFERENT PRODUCTION SITES, CAMBRIDGE, MASSACHUSETTS (USA) AND SIGNES (FRANCE). THE REFERENCE ONIVYDE (MANUFACTURED AT IPSEN CAMBRIDGE, USA) WILL BE COMPARED TO THE TEST ONIVYDE (MANUFACTURED AT IPSEN SIGNES, FRANCE).
Technical Summary
- PHASE I, RANDOMIZED, UNBLINDED, SINGLE-DOSE, TWO-STAGE, TWO-WAY CROSSOVER, RANDOMIZED, UNBLINDED, SINGLE-DOSE, TWO-STAGE, BI-THERAPY STUDY TO EVALUATE THE BIOEQUIVALENCE OF ONIVYDE (IRINOTECAN LIPOSOMAL INJECTION) MANUFACTURED AT TWO DIFFERENT CENTERS AND ADMINISTERED IN COMBINATION WITH ANTINEOPLASTICS IN ADULT PARTICIPANTS WITH METASTATIC PANCREATIC ADENOCARCINOMA.
- Code EudraCT: 2021-003264-26
- Protocol number: D-FR-60010-015
- Promoter: IPSEN
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.